A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.
Colo-rectal Cancer
DRUG: Arfolitixorin|DRUG: Leucovorin
Overall Response Rate, Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment., Until disease progression, an average of ten months
Progression Free Survival, PFS, defined as the time from randomization to first occurrence of tumor progression based on CT-scans/MRIs., Until disease progression, an average of ten months|Duration of Response, The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented., Until disease progression, an average of ten months
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.